Effects of Acute Intravenous Iloprost on Right Ventricular Hemodynamics in Rats with Chronic Pulmonary Hypertension

The inotropic effects of prostacyclins in chronic pulmonary arterial hypertension (PAH) are unclear and may be important in directing patient management in the acute setting. We sought to study the effects of an acute intravenous (IV) infusion of iloprost on right ventricular (RV) contractility in a rat model of chronic PAH. Rats were treated with monocrotaline, 60 mg/kg intraperitoneally, to induce PAH. Six weeks later, baseline hemodynamic assessment was performed with pressure-volume and Doppler flow measurements. In one group of animals, measurements were repeated 10–15 minutes after IV infusion of a fixed dose of iloprost (20 μg/kg). A separate group of rats underwent dose-response assessment. RV contractility and RV–pulmonary artery coupling were assessed by the end-systolic pressure-volume relationship (ESPVR) and end-systolic elastance/effective arterial elastance (Ees/Ea). RV cardiomyocytes were isolated, and intracellular cAMP (cyclic adenosine monophosphate) concentration was measured with a cAMP-specific enzyme immunoassay kit. Animals had evidence of PAH and RV hypertrophy. Right ventricle/(left ventricle + septum) weight was 0.40 ± 0.03. RV systolic pressure (RVSP) was 39.83 ± 1.62 mmHg. Administration of iloprost demonstrated an increase in the slope of the ESPVR from 0.29 ± 0.02 to 0.42 ± 0.05 (P < .05). Ees/Ea increased from 0.63 ± 0.07 to 0.82 ± 0.06 (P < .05). The RV contractility index (max dP/dt normalized for instantaneous pressure) increased from 94.11 to 114.5/s (P < .05), as did the RV ejection fraction, from 48.0% to 52.5% (P < .05). This study suggests a positive inotropic effect of iloprost on a rat model of chronic PAH.

[1]  D. Meldrum,et al.  Medical and surgical treatment of acute right ventricular failure. , 2010, Journal of the American College of Cardiology.

[2]  R. Naeije,et al.  Early right ventriculo-arterial uncoupling in borderline pulmonary hypertension on experimental heart failure. , 2010, Journal of applied physiology.

[3]  MarcHumbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010 .

[4]  M. Buckley,et al.  Inhaled Epoprostenol for the Treatment of Pulmonary Arterial Hypertension in Critically Ill Adults , 2010, Pharmacotherapy.

[5]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[6]  G. Butrous,et al.  Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. , 2009, The Journal of pediatrics.

[7]  Jeffrey L. Anderson,et al.  ACCF/AHA Expert Conseusus Document , 2009 .

[8]  P. Wouters,et al.  Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension , 2008, Critical care.

[9]  V. Džavík,et al.  Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease , 2008, Circulation.

[10]  Pál Pacher,et al.  Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats , 2008, Nature Protocols.

[11]  F. Haddad,et al.  Management strategies for patients with pulmonary hypertension in the intensive care unit* , 2007, Critical care medicine.

[12]  R. Naeije,et al.  How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. , 2007, American journal of respiratory and critical care medicine.

[13]  P. Wouters,et al.  Epoprostenol treatment of acute pulmonary hypertension is associated with a paradoxical decrease in right ventricular contractility , 2007, Intensive Care Medicine.

[14]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[15]  H. Suga,et al.  Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. , 2005, American journal of physiology. Heart and circulatory physiology.

[16]  Meeiyueh Liu,et al.  Both cGMP and peroxynitrite mediate chronic interleukin‐6‐induced negative inotropy in adult rat ventricular myocytes , 2005, The Journal of physiology.

[17]  Titus Kuehne,et al.  Magnetic Resonance Imaging Analysis of Right Ventricular Pressure-Volume Loops: In Vivo Validation and Clinical Application in Patients With Pulmonary Hypertension , 2004, Circulation.

[18]  R. Ritchie,et al.  Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling. , 2004, American journal of physiology. Heart and circulatory physiology.

[19]  R. Naeije,et al.  Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure* , 2004, Critical care medicine.

[20]  K. Schrör,et al.  Inotropic actions of eicosanoids , 2004, Basic Research in Cardiology.

[21]  W. Kuebler,et al.  The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo , 2003, Intensive Care Medicine.

[22]  Benoît Rondelet,et al.  Single-beat estimation of right ventricular end-systolic pressure-volume relationship. , 2003, American journal of physiology. Heart and circulatory physiology.

[23]  Orris,et al.  INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .

[24]  F. Fedele,et al.  Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension , 2001, Critical care.

[25]  R. Cody,et al.  A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. , 2000, Journal of cardiothoracic and vascular anesthesia.

[26]  G. Montalescot,et al.  Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. , 1998, The American journal of cardiology.

[27]  H. Bittner,et al.  Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. , 1997, The Annals of thoracic surgery.

[28]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[29]  S. Liu,et al.  G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes. , 1995, The American journal of physiology.

[30]  S. Narumiya,et al.  Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. , 1994, Circulation.

[31]  P. Fourie,et al.  Pulmonary artery compliance: its role in right ventricular-arterial coupling. , 1992, Cardiovascular research.

[32]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[33]  S Sasayama,et al.  Ventriculoarterial coupling in normal and failing heart in humans. , 1989, Circulation research.

[34]  P. Halushka,et al.  Thromboxane, prostaglandin and leukotriene receptors. , 1989, Annual review of pharmacology and toxicology.

[35]  K Sagawa,et al.  Ventricular efficiency predicted by an analytical model. , 1986, The American journal of physiology.

[36]  P. Dorigo,et al.  Positive inotropic effect of a stable analogue of PGI2 and of PGI2 on isolated guinea pig atria. Mechanism of action. , 1983, Pharmacological research communications.

[37]  O. V. Miller,et al.  Modulation of human platelet adenylate cyclase by prostacyclin (PGX). , 1977, Prostaglandins.